NCT04478071View on ClinicalTrials.gov

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

448

Participants

Timeline

Start Date

August 22, 2020

Primary Completion Date

March 7, 2022

Study Completion Date

March 25, 2022

Conditions
Acute Respiratory Distress SyndromeCoronavirus Infection
Interventions
DRUG

vadadustat

Participants will receive vadadustat once daily for 14 days.

DRUG

placebo

Participants will receive matching placebo once daily for 14 days.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

Sponsors

Collaborators (1)

Akebia Therapeutics Inc.
All Listed Sponsors
collaborator

Akebia Therapeutics Inc.

UNKNOWN

collaborator

United States Department of Defense

FED

lead

The University of Texas Health Science Center, Houston

OTHER

NCT04478071 - Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter